| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Merger Agreement Details and Path to Completion
Following the successful closing of the tender offer, BMS will acquire all remaining shares of 2seventy bio common stock that are not tendered in the tender offer through a second-step merger at the same price in the tender offer of $5.00 per share.
Following the completion of this transaction, 2seventy bio's common stock will no longer be listed for trading on Nasdaq.
In connection with the execution of the merger agreement, certain stockholders of 2seventy bio owning approximately 6.0% of the outstanding shares of 2seventy bio's common stock entered into tender and support agreements, pursuant to which they agreed to tender all of their shares in the offer.
In light of the announced transaction, 2seventy bio will not be hosting an earnings conference call or providing financial guidance for 2025.
Posted In: TSVT
